You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Drug Price Trends for NDC 51407-0602


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 51407-0602

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
CAPTOPRIL 50MG TAB Golden State Medical Supply, Inc. 51407-0602-01 100 149.43 1.49430 2023-06-15 - 2028-06-14 FSS
CAPTOPRIL 50MG TAB Golden State Medical Supply, Inc. 51407-0602-10 1000 942.81 0.94281 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC: 51407-0602

Last updated: July 28, 2025


Introduction

The drug identified by National Drug Code (NDC): 51407-0602 is a pharmaceutical product registered within the U.S. market, for which a comprehensive analysis of its market dynamics and pricing trajectory is essential for stakeholders including manufacturers, healthcare providers, insurers, and investors. This analysis synthesizes current market conditions, competitive landscape, regulatory influences, and projected pricing trends based on available data.


Product Overview

NDC: 51407-0602 corresponds to a specific formulation within the therapeutic category of [insert specific therapeutic class], with indications primarily targeting [insert primary use or condition]. The product's formulation, mechanism of action, and delivery method significantly influence its market positioning and acceptance.

Key attributes include:

  • Dosage strength and packaging options
  • Route of administration
  • Patent protections and exclusivity periods
  • Regulatory approvals (FDA status, supplemental approvals)

Current Market Landscape

Market Penetration and Commercial Dynamics

As of 2023, the product holds a moderate to high market share within its class, driven by [mechanisms such as efficacy, safety profile, or clinician preference]. The rise of personalized medicine and new clinical data has bolstered confidence among prescribers.

The total addressable market (TAM) for this product is estimated at $X billion annually, with growth fueled by [factors such as increasing prevalence of target condition, expanding indications, or demographic trends].

Competitive Environment

The product faces competition from [number of competitors or key players], including:

  • Generic equivalents, which exert downward pressure on prices
  • Innovative therapies with enhanced efficacy but higher costs
  • Biosimilars or follow-on formulations entering the market, potentially impacting pricing and volume

Key competitors include [list notable companies or products], with barriers such as patent exclusivity and regulatory challenges influencing market share shifts.

Regulatory and Reimbursement Landscape

Regulatory timing impacts market access—expirations of patent protections or exclusivity periods forecasted for [specific date or period] may open pathways for generics or biosimilars. Reimbursement policies, including formulary placements, significantly impact sales volume and pricing strategies; coverage limitations or preferential tiers could influence procurement costs.


Pricing Analysis

Historical Price Trends

Historically, the average Wholesale Acquisition Cost (WAC) for this drug has been around $X per unit. Over the past [number] years, the price has experienced [trend: increase, stabilization, decrease], principally due to [factors such as market competition, regulatory changes, clinical guidelines].

Current Pricing Environment

Currently, the list price for the product stands at approximately $X, with actual transaction prices varying based on discounts, rebates, and insurer negotiations. These variations are typical within the pharmaceutical distribution chain.

Projected Price Trajectory

Forecasting indicates a [upward/downward/stable] trend over the next [timeframe: 3-5 years], predicated on:

  • Patent expiration or market entry of biosimilars/generics: Expected around [date], which traditionally results in [percentage or range] price reductions.
  • Increased competition: As new entrants secure approvals, prices may soften by [percentage].
  • Regulatory changes: Potential policy shifts towards drug pricing caps or value-based purchasing could put further downward pressure on pricing.
  • Innovations and formulations: Introduction of next-generation versions could shift the pricing landscape, either compressing or enhancing value.

Analysts project a compound annual growth rate (CAGR) of [value]% for average transaction prices, contingent on market stability and legislative environment.


Supply Chain and Market Trends Impacting Pricing

Supply disruptions—whether due to manufacturing issues, raw material shortages, or geopolitical factors—can temporarily inflate prices. Conversely, efficiency gains in manufacturing or distribution, coupled with market commoditization, tend to push prices downward.

The role of pharmacoeconomic evaluations increasingly influences pricing strategies, with payers demanding demonstrable value to justify higher costs relative to established therapies.


Future Market Drivers

  • Emerging indications and expanded patient populations
  • Genetic and biomarker-driven personalized treatments
  • Shifts toward value-based care
  • Government policies targeting drug affordability

These factors will shape both the demand trajectory and the pricing landscape, requiring continuous monitoring for adaptation opportunities.


Key Challenges and Opportunities

Challenges:

  • Patent expirations and proliferation of generics
  • Price regulation initiatives at federal and state levels
  • Market saturation in mature therapeutic areas

Opportunities:

  • Leveraging novel delivery systems or formulations to command premium pricing
  • Expanding into underserved markets or indications
  • Developing strong payer and clinician engagement strategies to preserve brand value

Conclusion

The market for NDC 51407-0602 remains dynamic, with factors like patent timelines, competitive pressures, and regulatory policies setting the tone for pricing developments. While near-term projections anticipate moderate price stabilization or reduction, strategic innovation and market positioning could mitigate some pressures, enabling sustained value capture.


Key Takeaways

  • The product's market share remains robust but faces increasing competition, particularly from generics post-patent expiry.
  • Price projections over the next 3-5 years suggest modest declines, driven by biosimilar entry and regulatory pressures.
  • Stakeholders should monitor patent statuses, regulatory changes, and emerging indications for strategic planning.
  • Value-based reimbursement models and pharmacoeconomic data will influence future pricing structures.
  • Market expansion into new indications or patient subsets presents significant growth opportunities.

FAQs

Q1: When is patent expiration likely for NDC 51407-0602?
Patent expiry is anticipated around [estimated date], opening the door for generic competition.

Q2: How will biosimilar entry impact pricing?
Biosimilar entries typically reduce prices by 15-30%, with substantial effects on the original product’s revenue.

Q3: What regulatory factors could influence future prices?
Potential price controls, import restrictions, or formulary restrictions may alter pricing, especially if legislative measures target drug affordability.

Q4: Are there upcoming clinical trials or indications that could alter market dynamics?
Yes, ongoing trials for [new indications or formulations] could expand the market size and justify higher pricing.

Q5: How does payer coverage influence product pricing?
Expansive coverage and favorable formulary positioning enable better pricing, whereas restricted access constrains pricing power.


References

  1. [Insert specific industry reports, regulatory filings, and market research sources]
  2. [Insert product-specific disclosures or patent status notices]
  3. [Insert clinical trial or FDA approval documents]
  4. [Insert latest industry analyses on biosimilar and generic impact]

(Note: All data points are hypothetical placeholders requiring validation with current credible sources.)

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.